Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
Lucid Diagnostics (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ: PAVM), announced its upcoming inclusion in both the Russell 2000® Index and Russell 3000® Index. The inclusion will be effective after market close on June 27, 2025, as part of the annual reconstitution. The Russell 3000 Index comprises the largest 3,000 U.S. public companies by market cap, while the Russell 2000 focuses on small-cap companies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes, which are widely used by investment managers and institutional investors.
Lucid Diagnostics (NASDAQ: LUCD), azienda di diagnostica medica per la prevenzione del cancro in fase commerciale e controllata da PAVmed (NASDAQ: PAVM), ha annunciato la sua prossima inclusione sia nel Russell 2000® Index sia nel Russell 3000® Index. L'inclusione avrà effetto dopo la chiusura del mercato il 27 giugno 2025, nell'ambito della ristrutturazione annuale. L'indice Russell 3000 comprende le 3.000 maggiori società pubbliche statunitensi per capitalizzazione di mercato, mentre il Russell 2000 si concentra sulle società a piccola capitalizzazione. Secondo FTSE Russell, circa 10,6 trilioni di dollari in asset sono indicizzati rispetto agli indici Russell USA, ampiamente utilizzati da gestori di investimenti e investitori istituzionali.
Lucid Diagnostics (NASDAQ: LUCD), una empresa de diagnóstico médico para la prevención del cáncer en etapa comercial y subsidiaria de PAVmed (NASDAQ: PAVM), anunció su próxima inclusión en el Russell 2000® Index y el Russell 3000® Index. La inclusión será efectiva después del cierre del mercado el 27 de junio de 2025, como parte de la reconstitución anual. El índice Russell 3000 incluye las 3,000 mayores empresas públicas de EE.UU. por capitalización de mercado, mientras que el Russell 2000 se enfoca en empresas de pequeña capitalización. Según FTSE Russell, aproximadamente 10.6 billones de dólares en activos están referenciados a los índices Russell de EE.UU., ampliamente usados por gestores de inversiones e inversores institucionales.
루시드 다이아그노스틱스 (NASDAQ: LUCD)는 상업 단계의 암 예방 의료 진단 회사이자 PAVmed (NASDAQ: PAVM)의 자회사로서, 러셀 2000® 지수와 러셀 3000® 지수에 곧 포함될 예정임을 발표했습니다. 이 포함은 2025년 6월 27일 시장 마감 후에 발효되며, 연례 재구성의 일환입니다. 러셀 3000 지수는 시가총액 기준으로 미국 내 상위 3,000개 상장 기업을 포함하며, 러셀 2000은 소형주에 중점을 둡니다. FTSE 러셀에 따르면 약 10.6조 달러의 자산이 러셀 미국 지수를 벤치마크로 삼고 있으며, 이는 투자 관리자와 기관 투자자들 사이에서 널리 사용되고 있습니다.
Lucid Diagnostics (NASDAQ : LUCD), une entreprise de diagnostic médical en phase commerciale spécialisée dans la prévention du cancer et filiale de PAVmed (NASDAQ : PAVM), a annoncé sa prochaine inclusion dans les Russell 2000® Index et Russell 3000® Index. Cette inclusion prendra effet après la clôture des marchés le 27 juin 2025, dans le cadre de la reconstitution annuelle. L'indice Russell 3000 regroupe les 3 000 plus grandes entreprises publiques américaines par capitalisation boursière, tandis que le Russell 2000 se concentre sur les petites capitalisations. Selon FTSE Russell, environ 10,6 billions de dollars d'actifs sont indexés sur les indices Russell US, largement utilisés par les gestionnaires d'investissements et les investisseurs institutionnels.
Lucid Diagnostics (NASDAQ: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention in der kommerziellen Phase und Tochtergesellschaft von PAVmed (NASDAQ: PAVM), gab seine bevorstehende Aufnahme sowohl in den Russell 2000® Index als auch in den Russell 3000® Index bekannt. Die Aufnahme wird nach Börsenschluss am 27. Juni 2025 im Rahmen der jährlichen Neuzusammensetzung wirksam. Der Russell 3000 Index umfasst die 3.000 größten börsennotierten US-Unternehmen nach Marktkapitalisierung, während sich der Russell 2000 auf Small-Cap-Unternehmen konzentriert. Laut FTSE Russell werden rund 10,6 Billionen US-Dollar an Vermögenswerten an den Russell US-Indizes gemessen, die von Investmentmanagern und institutionellen Anlegern weit verbreitet genutzt werden.
- Inclusion in Russell 2000 and Russell 3000 indexes increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index-linked financial products
- Recognition of company's progress in enhancing shareholder value
- None.
"We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Dennis McGrath, Lucid's Chief Financial Officer. "This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors."
The broad-market Russell 3000 Index includes the largest 3,000
For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
About FTSE Russell
FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-join-russell-2000-and-russell-3000-indexes-302465481.html
SOURCE Lucid Diagnostics
FAQ
When will Lucid Diagnostics (LUCD) join the Russell 2000 and Russell 3000 indexes?
What is the significance of LUCD joining the Russell indexes?
How long will Lucid Diagnostics remain in the Russell indexes?
What is Lucid Diagnostics' relationship with PAVmed?
What type of company is LUCD?
